组织陈列-产品详情

home > TISSUE ARRAYS > Multiple organ > MBC1901

Type
- FFPE
- FROZEN TISSUE
Identity
Organ
- Liver
- Esophagus
- Ovary
- Stomach
- Lung
- Colon
- Rectum
- Kidney
- Breast
- Endometrium
- Uterus
- Bladder
- Pancreas
- Skin
- Penis
- Testis
- Soft_Tissue
- Bone/Cartilage
- Oral/Cavity
- Bone/Marrow
- Heart
- Spleen
- Head/Neck
- Vulva
- Melanoma
- Appendix
- Intestine
- Adrenal Gland
- Thymus
- Fallopian tube
- Mouse
- Fetus
- Rat
- Monkey (Rhesus) (Normal)-RsFPT
- Monkey (Cynomolgus) (Normal)-CyFPT
- Dog
- Multiple organ
- Gall bladder and bile duct
- Esophagogastric junction
Types/Disease
Cores
Cases

Cores:

190

CASES:

190

Core Diameter(mm):

1

Thickness(µm):

5

Row number:

12

Column number:

16

Tissue Array Type:

FFPE

Species:

Human

MBC1901

$395.00

Add To Collect

Description: Multi-organ carcinoma tissue array, including pathology grade, TNM and clinical stage, 190 cases/190 cores

Details: Multi-organ carcinoma tissue microarray, containing 38 cases each of breast invasive carcinoma of no special type, lung squamous cell carcinoma, colon adenocarcinoma, prostate adenocarcinoma and pancreas carcinoma, single core per case

Applications: Routine histology procedures including Immunohistochemistry (IHC) and In Situ Hybridization (ISH), protocols which can be found at our support page

Please Select Tissue Array Type:

Unstained

H&E

Tag:

190 Cores 190 Cases Multiple organ multiple organs special price single core per case

Add To Cart

Outright purchase

Note

1. TMA slides were sectioned and stored at 4°C and may not be fresh cut, but still suitable for IHC. Please request fresh cut if experiment involves phospho-specific antibodies, RNA studies, FISH or ISH, etc. A minimum of 3 slides per TMA must be purchased to cover the cost of trimming for fresh sectioning.
2. Most TMA slides were not coated with an extra layer of paraffin (tissue cores can be easily seen on the glass). To prevent tissue detachment during antigen retrieval, unbaked slides must be baked for at least 30 to 120 minutes at 60°C. before putting into xylene for de-paraffinization. Baked slides were sent out baked for 2 hours.
In the following specsheet,“*” means invalid core; “-” means no applicable or negative in IHC markers."

Specification sheet
Overlapping case
Download specifications

Legend:

Car-Cardia Eso-Fsophagus

Malignant(I)
Malignant(IA)
Malignant(IB)
Malignant(IIA)
Malignant(IIB)
Malignant(II)
Malignant(IIIA)
Malignant(IIIB)
Malignant(IIIC)
Malignant(III)
Malignant(IV)

TISSUE ARRAYS
MBC1901

	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16
A	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre
B	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre
C	Bre	Bre	Bre	Bre	Bre	Bre	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun
D	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun
E	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Col	Col	Col	Col
F	Col	Col	Col	Col	Col	Col	Col	Col	Col	Col	Col	Col	Col	Col	Col	Col
G	Col	Col	Col	Col	Col	Col	Col	Col	Col	Col	Col	Col	Col	Col	Col	Col
H	Col	Col	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Pro
I	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Pro
J	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Pan	Pan	Pan	Pan	Pan	Pan	Pan	Pan
K	Pan	Pan	Pan	Pan	Pan	Pan	Pan	Pan	Pan	Pan	Pan	Pan	Pan	Pan	Pan	Pan
L	Pan	Pan	Pan	Pan	Pan	Pan	Pan	Pan	Pan	Pan	Pan	Pan	Pan	Pan

MBC1901

Age:
Sex:
Organ/Anatomic Site:
Pathology diagnosis:
Grade:
TNM:
Stage:
Tissue ID.:
Type:

Pos	No.	Age	Sex	Organ/Anatomic Site	Pathology diagnosis	Grade	TNM	Stage	Type	Tumor size	Gleason Grade	Gleason Score	Ki-67	CK
A1	1	43	F	Breast	Invasive carcinoma of no special type with sparse necrosis	1	T3N0M0	IIB	Malignant	5*3	-	-	+，20%	++，90%
A2	2	75	F	Breast	Invasive carcinoma of no special type	1	T3N1M0	IIIA	Malignant	12*9	-	-	-	++，90%
A3	3	32	F	Breast	Invasive carcinoma of no special type	1--2	T3N1M0	IIIA	Malignant	12*8	-	-	+，15%	++，90%
A4	4	55	F	Breast	Invasive carcinoma of no special type	1--2	T4N1M0	IIIB	Malignant	332.5	-	-	弱+，5%	++，90%
A5	5	52	F	Breast	Invasive carcinoma of no special type	2	T2N0M0	IIA	Malignant	-	-	-	++，35%	++，90%
A6	6	54	F	Breast	Invasive carcinoma of no special type	2	T2N1M0	IIB	Malignant	32.51.0	-	-	-	+++，100%
A7	7	48	F	Breast	Invasive carcinoma of no special type	2	T3N0M0	IIB	Malignant	752.5	-	-	+，20%	++，90%
A8	8	30	F	Breast	Invasive carcinoma of no special type	2	T2N0M0	IIA	Malignant	3.52.51.0	-	-	+，5%	+++，100%
A9	9	54	F	Breast	Invasive carcinoma of no special type	2	T3N0M0	IIB	Malignant	3.03.02.5	-	-	+，5%	+++，100%
A10	10	55	F	Breast	Invasive carcinoma of no special type (sparse)	2	T2N2M0	IIIA	Malignant	-	-	-	-	++，90%
A11	11	29	F	Breast	Invasive carcinoma of no special type (interstitial)	2	T2N0M0	IIA	Malignant	-	-	-	-	-
A12	12	87	F	Breast	Invasive carcinoma of no special type	2	T2N1M0	IIB	Malignant	5*5	-	-	-	++，90%
A13	13	44	F	Breast	Invasive carcinoma of no special type	2	T2N2M0	IIIA	Malignant	2.511	-	-	+，5%	++，90%
A14	14	42	F	Breast	Invasive carcinoma of no special type	2	T2N1M0	IIB	Malignant	542.5	-	-	-	+，70%
A15	15	52	F	Breast	Invasive carcinoma of no special type (sparse)	2	T2N1M0	IIB	Malignant	2*2	-	-	-	+，70%
A16	16	42	F	Breast	Invasive carcinoma of no special type (sparse)	2	T4N2M0	IIIB	Malignant	662	-	-	+，20%	++，90%
B1	17	55	F	Breast	Invasive carcinoma of no special type	2	T3N2M0	IIIB	Malignant	-	-	-	+，10%	++，90%
B2	18	43	F	Breast	Invasive carcinoma of no special type	2	T2N1M0	IIB	Malignant	-	-	-	++，30%	+++，100%
B3	19	37	F	Breast	Invasive carcinoma of no special type with degeneration	2	T2N1M0	IIB	Malignant	2.522	-	-	-	++，90%
B4	20	38	F	Breast	Invasive carcinoma of no special type	2	T3N0M0	IIB	Malignant	5*4	-	-	+，20%	+++，100%
B5	21	48	F	Breast	Invasive carcinoma of no special type	2	T2N2M0	IIIA	Malignant	2*2	-	-	++，80%	+++，100%
B6	22	37	F	Breast	Invasive carcinoma of no special type	2	T2N2M0	IIIA	Malignant	532	-	-	+，5%	+++，100%
B7	23	48	F	Breast	Invasive carcinoma of no special type	2	T1N1M0	IIA	Malignant	-	-	-	+，3%	+++，100%
B8	24	46	F	Breast	Invasive carcinoma of no special type (interstitial)	2	T3N2M0	IIIA	Malignant	9*5	-	-	-	-
B9	25	68	F	Breast	Invasive carcinoma of no special type	2	T3N0M0	IIB	Malignant	1795	-	-	-	++，90%
B10	26	51	F	Breast	Invasive carcinoma of no special type	2	T2N2M0	IIIA	Malignant	3*3	-	-	+，10%	++，90%
B11	27	52	F	Breast	Invasive carcinoma of no special type	2	T4N1M0	IIIB	Malignant	7*3	-	-	+，30%	++，90%
B12	28	52	F	Breast	Invasive carcinoma of no special type	2	T3N1M0	IIIA	Malignant	5*4.5	-	-	-	++，90%
B13	29	42	F	Breast	Invasive carcinoma of no special type	2	T3N0M0	IIB	Malignant	654	-	-	+，15%	++，90%
B14	30	41	F	Breast	Invasive carcinoma of no special type (containing ductal carcinoma in situ)	2	T2N0M0	IIA	Malignant	5*2.2	-	-	+，10%	++，90%
B15	31	47	F	Breast	Invasive carcinoma of no special type	2	T4N1M0	IIIB	Malignant	2.522	-	-	+，3%	+++，100%
B16	32	32	F	Breast	Invasive carcinoma of no special type with sparse necrosis	2	T4N1M0	IIIB	Malignant	533	-	-	+，15%	++，90%
C1	33	32	F	Breast	Invasive carcinoma of no special type with degeneration	2	T2N1M0	IIB	Malignant	5*3	-	-	+，5%	+，90%
C2	34	53	F	Breast	Invasive carcinoma of no special type	2--3	T2N2M0	IIIA	Malignant	43	-	-	+，30%	++，90%
C3	35	59	F	Breast	Invasive carcinoma of no special type	2--3	T2N0M0	IIA	Malignant	:64.53.0	-	-	+，10%	++，90%
C4	36	38	F	Breast	Invasive carcinoma of no special type with sparse necrosis	2--3	T2N0M0	IIA	Malignant	-	-	-	-	++，90%
C5	37	51	F	Breast	Invasive carcinoma of no special type with sparse necrosis	3	T3N1M0	IIIA	Malignant	64.53.0	-	-	+，30%	++，90%
C6	38	58	F	Breast	Invasive carcinoma of no special type	3	T2N1M0	IIB	Malignant	-	-	-	++，40%	+++，100%
C7	39	63	M	Lung	Squamous cell carcinoma with sparse necrosis	1	T2N0M0	IB	Malignant	543.5	-	-	+，10%	++，90%
C8	40	53	M	Lung	Squamous cell carcinoma	1	T2N1M0	II	Malignant	6.355	-	-	+，3%	++，90%
C9	41	55	M	Lung	Squamous cell carcinoma	2	T2N0M0	IB	Malignant	5.54.03.0	-	-	+，30%	+，90%
C10	42	60	M	Lung	Squamous cell carcinoma	2	T2N2M0	IIIA	Malignant	4.53.03.0	-	-	+，20%	++，90%
C11	43	58	M	Lung	Squamous cell carcinoma	2	T2N0M0	IB	Malignant	4.54.03.0	-	-	+，40%	++，90%
C12	44	55	M	Lung	Squamous cell carcinoma (sparse)	2	T2aN1M0	IIA	Malignant	5.04.03.5	-	-	-	++，90%
C13	45	55	F	Lung	Squamous cell carcinoma (sparse)	2	T2aN0M0	IB	Malignant	5	-	-	+，30%	++，90%
C14	46	63	M	Lung	Squamous cell carcinoma with necrosis	2	T2N0M0	IB	Malignant	6.05.04.5	-	-	++，30%	++，90%
C15	47	48	M	Lung	Squamous cell carcinoma with necrosis	2	T2aN0M0	IB	Malignant	3.53.02.0	-	-	+，30%	++，90%
C16	48	54	M	Lung	Squamous cell carcinoma (sparse)	2	T2aN0M0	IB	Malignant	4.53.03.0	-	-	-	肺泡上皮 ++,80%
D1	49	61	M	Lung	Squamous cell carcinoma	2	T2N1M0	IIA	Malignant	5.03.03.0	-	-	+，30%	++，90%
D2	50	42	F	Lung	Squamous cell carcinoma (necrosis)	*	T2aN0M0	IB	Malignant	4.03.52.0	-	-	-	+，70%
D3	51	35	F	Lung	Squamous cell carcinoma	2	T2aN0M0	IB	Malignant	4.53.53.0	-	-	++，40%	++，90%
D4	52	48	F	Lung	Squamous cell carcinoma with sparse necrosis	2	T2bN0M0	IIA	Malignant	4.54.54.0	-	-	++，35%	++，90%
D5	53	58	M	Lung	Squamous cell carcinoma (sparse)	2	T2aN0M0	IB	Malignant	4.03.52.0	-	-	+，30%	++，90%
D6	54	51	M	Lung	Squamous cell carcinoma with necrosis	2	T2aN0M0	IB	Malignant	5.05.03.5	-	-	+，30%	++，90%
D7	55	60	F	Lung	Squamous cell carcinoma	2	T2N0M0	IB	Malignant	3.02.52.5	-	-	+，30%	++，90%
D8	56	46	F	Lung	Squamous cell carcinoma	2	T2N0M0	IB	Malignant	4.54.03.0	-	-	++，40%	++，90%
D9	57	57	M	Lung	Squamous cell carcinoma	2	T2N1M0	IIB	Malignant	7.562	-	-	+，5%	++，90%
D10	58	57	F	Lung	Squamous cell carcinoma	2	T2N0M0	IB	Malignant	4.842.8	-	-	+，15%	++，90%
D11	59	71	M	Lung	Squamous cell carcinoma	2	T2bN1M0	IIB	Malignant	65.83.5	-	-	++，35%	++，90%
D12	60	68	M	Lung	Squamous cell carcinoma	2	T2N0M0	IB	Malignant	543	-	-	-	++，90%
D13	61	70	M	Lung	Squamous cell carcinoma	2	T2AN0M0	IB	Malignant	54.03.0	-	-	+，60%	+++，100%
D14	62	56	M	Lung	Squamous cell carcinoma (lung tissue)	*	T2N0M0	IB	Malignant	-	-	-	肺泡上皮-	肺泡上皮 ++,80%
D15	63	58	M	Lung	Squamous cell carcinoma	3	T2N3M0	IIIB	Malignant	5.04.03.5	-	-	+，3%	++，90%
D16	64	59	M	Lung	Squamous cell carcinoma	3	T2N1M0	IIB	Malignant	6.55.04.0	-	-	+，50%	++，90%
E1	65	56	M	Lung	Squamous cell carcinoma	2--3	T2N0M0	IB	Malignant	543.5	-	-	-	++，90%
E2	66	49	M	Lung	Squamous cell carcinoma	3	T2N1M0	IIA	Malignant	4.5*4	-	-	+，40%	++，90%
E3	67	42	M	Lung	Squamous cell carcinoma with degeneration	3	T2N0M0	IB	Malignant	5*4	-	-	-	+，70%
E4	68	60	M	Lung	Squamous cell carcinoma	3	T3N1M0	IIIA	Malignant	6	-	-	+，5%	++，90%
E5	69	50	M	Lung	Squamous cell carcinoma	*	T2aN0M0	IB	Malignant	4.02.52.0	-	-	+，60%	++，90%
E6	70	65	M	Lung	Squamous cell carcinoma	3	T2bN0M0	IIA	Malignant	5.03.52.5	-	-	+，10%	++，90%
E7	71	66	M	Lung	Squamous cell carcinoma	3	T2aN0M0	IB	Malignant	4.04.02.5	-	-	-	++，90%
E8	72	57	M	Lung	Squamous cell carcinoma with degeneration	3	T3N0M0	IIB	Malignant	8.05.03.5	-	-	-	++，90%
E9	73	74	M	Lung	Squamous cell carcinoma	3	T2bN0M0	IIA	Malignant	4.04.02.5	-	-	+，30%	++，90%
E10	74	46	M	Lung	Squamous cell carcinoma with necrosis	3	T3N1M0	IIIA	Malignant	5.5	-	-	+，40%	+，30%
E11	75	57	M	Lung	Squamous cell carcinoma	3	T2bN0M0	IIA	Malignant	5.04.54.0	-	-	+，8%	+，70%
E12	76	48	M	Lung	Squamous cell carcinoma (chronic inflammation of lung tissue)	*	T2aN0M0	IB	Malignant	4.03.02.5	-	-	-	++，90%
E13	77	77	M	Colon	Adenocarcinoma	1	T2N0M0	I	Malignant	-	-	-	++，40%	+，70%
E14	78	76	F	Colon	Adenocarcinoma	1	T3N0M0	IIA	Malignant	-	-	-	+，30%	++，90%
E15	79	54	M	Colon	Adenocarcinoma (interstitial)	*	T3N0M0	IIA	Malignant	-	-	-	-	-
E16	80	72	M	Colon	Adenocarcinoma	1--2	T3N0M0	IIA	Malignant	552	-	-	+，30%	+，70%
F1	81	60	M	Colon	Adenocarcinoma (necrosis)	1--2	T3N0M0	IIA	Malignant	-	-	-	++，70%	+，80%
F2	82	87	M	Colon	Adenocarcinoma	1--2	T2N0M0	IB	Malignant	4.531	-	-	-	+，40%
F3	83	62	F	Colon	Adenocarcinoma	2	T3N1M0	IIIB	Malignant	-	-	-	+，50%	++，90%
F4	84	65	M	Colon	Adenocarcinoma	2	T3N2M0	IIIB	Malignant	-	-	-	+，30%	++，90%
F5	85	48	M	Colon	Adenocarcinoma (sparse)	2	T3N0M0	IIA	Malignant	-	-	-	+，30%	+++，100%
F6	86	72	M	Colon	Adenocarcinoma	2	T3N0M0	IIA	Malignant	-	-	-	-	++，90%
F7	87	35	F	Colon	Adenocarcinoma	2	T3N0M0	IIA	Malignant	-	-	-	+，40%	+++，100%
F8	88	72	F	Colon	Adenocarcinoma	2	T3N0M0	IIA	Malignant	-	-	-	+，10%	++，90%
F9	89	46	M	Colon	Adenocarcinoma (part mucinous adenocarcinoma)	2	T3N1M0	IIIB	Malignant	-	-	-	+，15%	++，90%
F10	90	56	F	Colon	Adenocarcinoma	2	T3N0M0	IIA	Malignant	-	-	-	+，40%	++，90%
F11	91	58	M	Colon	Adenocarcinoma	2	T3N2M0	IIIC	Malignant	6.54.51.5	-	-	+，40%	+，90%
F12	92	30	M	Colon	Adenocarcinoma	2	T3N0M0	IIA	Malignant	6.54.51.0	-	-	+，60%	+++，100%
F13	93	63	F	Colon	Adenocarcinoma	2	T3N0M0	IIA	Malignant	4.54.00.5	-	-	++，80%	++，90%
F14	94	75	F	Colon	Adenocarcinoma with degeneration	2	T3N0M0	IIA	Malignant	656	-	-	-	+，70%
F15	95	56	M	Colon	Adenocarcinoma	2	T3N2M0	IIIC	Malignant	-	-	-	+，40%	++，90%
F16	96	73	F	Colon	Adenocarcinoma	2	T3N2aM0	IIIB	Malignant	330.5cm	-	-	+，40%	++，90%
G1	97	71	M	Colon	Adenocarcinoma (part mucinous adenocarcinoma)	2	T4aN0M0	IIB	Malignant	-	-	-	+，30%	++，90%
G2	98	56	M	Colon	Adenocarcinoma	2	T4aN0M0	IIB	Malignant	-	-	-	++，40%	+，80%
G3	99	64	F	Colon	Adenocarcinoma	2	T4aN0M0	IIB	Malignant	5.55.02.5	-	-	+，40%	++，90%
G4	100	63	M	Colon	Adenocarcinoma with sparse necrosis	2	T4aN1M0	IIIB	Malignant	5.04.01.5	-	-	-	++，90%
G5	101	50	F	Colon	Adenocarcinoma	2	T4aN2bM0	IIIC	Malignant	656	-	-	-	++，90%
G6	102	66	M	Colon	Adenocarcinoma	2	T3N0M0	IIA	Malignant	4.54.00.5	-	-	+，60%	+++，100%
G7	103	73	M	Colon	Adenocarcinoma	2	T3N0M0	IIA	Malignant	4.54.50.5	-	-	++，70%	++，90%
G8	104	69	M	Colon	Adenocarcinoma (mucosa tissue)	2	T3N0M0	IIA	Malignant	-	-	-	+，30%	+，60%
G9	105	33	M	Colon	Adenocarcinoma	2	T3N0M0	IIA	Malignant	-	-	-	+，70%	+++，100%
G10	106	39	F	Colon	Adenocarcinoma with sparse necrosis	2	T3N0M0	IIA	Malignant	-	-	-	+，40%	++，90%
G11	107	52	M	Colon	Adenocarcinoma (part mucinous adenocarcinoma)	2	T3N0M0	IIA	Malignant	-	-	-	++，70%	+，80%
G12	108	64	M	Colon	Adenocarcinoma (part mucinous adenocarcinoma)	2	T3N0M0	IIA	Malignant	-	-	-	+，30%	+，90%
G13	109	45	F	Colon	Adenocarcinoma (part mucinous adenocarcinoma)	2	T3N0M0	IIA	Malignant	-	-	-	+，50%	+，80%
G14	110	65	F	Colon	Adenocarcinoma (part mucinous adenocarcinoma)	2	T3N0M0	IIA	Malignant	-	-	-	+，40%	++，90%
G15	111	65	M	Colon	Adenocarcinoma with sparse necrosis	2	7T4N0M0	IIB	Malignant	3*3.5	-	-	+，60%	++，80%
G16	112	65	F	Colon	Adenocarcinoma	2	T3N0M0	IIA	Malignant	43.00.5	-	-	+，30%	++，90%
H1	113	50	M	Colon	Adenocarcinoma with sparse necrosis	3	T3N2M0	IIIB	Malignant	6.54.50.5	-	-	+，70%	++，90%
H2	114	60	F	Colon	Adenocarcinoma	3	T3N1M0	III	Malignant	575	-	-	+，60%	++，90%
H3	115	71	M	Prostate	Adenocarcinoma	*	T2N0M0	I	Malignant	-	1	2+2	-	+，50%
H4	116	66	M	Prostate	Adenocarcinoma	*	T2N0M0	II	Malignant	654	1	2+2	-	+，70%
H5	117	60	M	Prostate	Adenocarcinoma	*	T4N1M1	IV	Malignant	-	5	5+5	+，5%	++，90%
H6	118	76	M	Prostate	Adenocarcinoma	*	T3bN0M0	III	Malignant	-	5	5+4	-	++，90%
H7	119	69	M	Prostate	Adenocarcinoma	*	T3N0M0	III	Malignant	432	1	3+3	+，3%	+，70%
H8	120	73	M	Prostate	Adenocarcinoma	*	T3N0M0	III	Malignant	-	1	3+3	-	+，20%
H9	121	63	M	Prostate	Adenocarcinoma	*	T3N1M1	IV	Malignant	-	3	4+3	-	++，90%
H10	122	60	M	Prostate	Adenocarcinoma	*	T2N0M0	II	Malignant	4.542	2	3+4	-	+++，100%
H11	123	68	M	Prostate	Adenocarcinoma	*	T2bN0M0	IIA	Malignant	875	3	4+3	-	+，40%
H12	124	73	M	Prostate	Adenocarcinoma	*	T2N0M0	II	Malignant	43.53	2	3+4	+，3%	+，50%
H13	125	73	M	Prostate	Adenocarcinoma	*	T2aN0M0	IIA	Malignant	-	2	3+4	-	++，90%
H14	126	62	M	Prostate	Adenocarcinoma	*	T3N0M0	III	Malignant	433	3	4+3	+，3%	+，40%
H15	127	60	M	Prostate	Adenocarcinoma	*	T2N0M0	IIB	Malignant	333	5	5+5	-	+，30%
H16	128	80	M	Prostate	Adenocarcinoma	*	T3N0M0	III	Malignant	-	4	4+4	+，3%	+，20%
I1	129	66	M	Prostate	Adenocarcinoma	*	T2N0M0	I	Malignant	321	3	4+3	+，5%	++，90%
I2	130	70	M	Prostate	Adenocarcinoma	*	T2aN0M0	IIA	Malignant	422	2	3+4	-	+，70%
I3	131	75	M	Prostate	Adenocarcinoma	*	T2N0M0	II	Malignant	-	4	4+4	+，3%	+，80%
I4	132	61	M	Prostate	Adenocarcinoma	*	T3N1M0	III	Malignant	-	4	4+4	+，5%	+，50%
I5	133	69	M	Prostate	Adenocarcinoma	*	T2aN0M0	IIA	Malignant	664.5	2	3+4	-	++，90%
I6	134	57	M	Prostate	Adenocarcinoma (sparse)	*	T2aN0M0	IIA	Malignant	344	5	5+4	+，5%	++，90%
I7	135	70	M	Prostate	Adenocarcinoma	*	T3N0M0	III	Malignant	742.5	4	4+4	-	弱+，30%
I8	136	70	M	Prostate	Adenocarcinoma	*	T3N0M0	III	Malignant	733.5	4	4+4	-	+，60%
I9	137	20	M	Prostate	Adenocarcinoma	*	T3N0M0	III	Malignant	654	4	4+4	-	+，20%
I10	138	62	M	Prostate	Adenocarcinoma	*	T3N0M0	III	Malignant	-	4	4+4	+，3%	++，90%
I11	139	75	M	Prostate	Adenocarcinoma	*	T2N0M0	II	Malignant	-	-	-	掉片	掉片
I12	140	72	M	Prostate	Adenocarcinoma	*	T3N0M0	III	Malignant	-	5	4+5	+，3%	++，90%
I13	141	60	M	Prostate	Adenocarcinoma (interstitial)	*	T3AN0M0	III	Malignant	-	-	-	-	-
I14	142	72	M	Prostate	Adenocarcinoma	*	T2N0M0	II	Malignant	532	5	5+4	+，8%	++，90%
I15	143	74	M	Prostate	Adenocarcinoma	*	T2N0M0	II	Malignant	643	5	4+5	-	+，70%
I16	144	60	M	Prostate	Adenocarcinoma	*	T3N0M0	III	Malignant	-	4	5+3	+，1%	++，90%
J1	145	65	M	Prostate	Adenocarcinoma	*	T2N0M0	II	Malignant	332	5	4+5	+，15%	++，90%
J2	146	56	M	Prostate	Adenocarcinoma	*	T3N0M0	III	Malignant	3*2.5	5	4+5	-	++，90%
J3	147	82	M	Prostate	Adenocarcinoma	*	T2bN0M0	IIA	Malignant	-	5	5+4	+，30%	++，90%
J4	148	81	M	Prostate	Adenocarcinoma	*	T3aN0M0	III	Malignant	654	3	4+3	-	+，30%
J5	149	66	M	Prostate	Adenocarcinoma	*	T3aN0M0	III	Malignant	4.544	5	4+5	+，5%	++，90%
J6	150	63	M	Prostate	Adenocarcinoma (degeneration)	*	T2N0M0	II	Malignant	-	5	5+5	-	+，20%
J7	151	68	M	Prostate	Adenocarcinoma	*	T2N0M0	IIA	Malignant	544	5	5+5	-	+，10%
J8	152	75	M	Prostate	Adenocarcinoma	*	T3N1M0	III	Malignant	522	5	5+5	-	++，90%
J9	153	58	F	Pancreas	Adenocarcinoma with necrosis	1	T3N1M0	IIB	Malignant	-	-	-	+，5%	++，90%
J10	154	31	F	Pancreas	Adenocarcinoma	1	T3N1M0	IIB	Malignant	421	-	-	-	+，70%
J11	155	42	M	Pancreas	Adenocarcinoma	1	T2N0M0	IB	Malignant	-	-	-	+，3%	++，90%
J12	156	44	F	Pancreas	Adenocarcinoma	1	T3N1M0	IIB	Malignant	-	-	-	-	+++，100%
J13	157	40	M	Pancreas	Adenocarcinoma	1	T2N1M0	IIB	Malignant	-	-	-	-	++，90%
J14	158	56	F	Pancreas	Adenocarcinoma	1--2	T3N1M0	IIB	Malignant	-	-	-	-	++，90%
J15	159	59	M	Pancreas	Adenocarcinoma	2	T2N1M0	IIB	Malignant	-	-	-	-，掉片	++，90%
J16	160	62	M	Pancreas	Adenocarcinoma	2	T3N1M0	IIB	Malignant	-	-	-	-	++，90%
K1	161	77	M	Pancreas	Adenocarcinoma (sparse)	2	T1N0M0	IA	Malignant	-	-	-	+，10%	++，90%
K2	162	76	M	Pancreas	Adenocarcinoma	2	T3N0M0	IIA	Malignant	-	-	-	+，5%	++，90%
K3	163	62	M	Pancreas	Adenocarcinoma	2	T2N0M0	IB	Malignant	333	-	-	-	++，90%
K4	164	55	M	Pancreas	Adenocarcinoma	2	T3N0M0	IIA	Malignant	-	-	-	+，10%	++，90%
K5	165	80	M	Pancreas	Adenocarcinoma	2	T2N0M0	IB	Malignant	-	-	-	+，5%	+++，100%
K6	166	54	M	Pancreas	Adenocarcinoma	2	T4N0M0	III	Malignant	-	-	-	+，10%	+++，100%
K7	167	52	M	Pancreas	Adenocarcinoma	2--3	T2N0M0	I	Malignant	3.5*3	-	-	+，10%	++，90%
K8	168	62	F	Pancreas	Adenocarcinoma	3	T3N0M0	IIA	Malignant	-	-	-	+，5%	++，90%
K9	169	39	F	Pancreas	Adenocarcinoma	2--3	T3N0M0	IIA	Malignant	431	-	-	-	++，90%
K10	170	66	F	Pancreas	Adenocarcinoma	3	T3N1M0	IIB	Malignant	-	-	-	-	++，90%
K11	171	62	F	Pancreas	Adenocarcinoma	3	T3N0M0	IIA	Malignant	654	-	-	-	++，90%
K12	172	56	M	Pancreas	Adenocarcinoma with neuroendocrine cancer differentiation	3	T2N0M0	IB	Malignant	986	-	-	+，30%	+，20%
K13	173	55	M	Pancreas	Adenocarcinoma	3	T2N0M0	IB	Malignant	542	-	-	-	++，90%
K14	174	55	M	Pancreas	Adenocarcinoma	3	T2N0M0	IB	Malignant	-	-	-	+，30%	弱+，10%
K15	175	50	M	Pancreas	Adenocarcinoma (degeneration)	3	T3N1M0	IIB	Malignant	542	-	-	+，5%	++，90%
K16	176	61	F	Pancreas	Adenocarcinoma (necrosis)	3	T2N0M0	IB	Malignant	-	-	-	-	-
L1	177	64	M	Pancreas	Adenocarcinoma (degeneration)	3	T3N0M0	IIA	Malignant	442	-	-	+，10%	++，90%
L2	178	69	M	Pancreas	Adenocarcinoma with degeneration and necrosis	2--3	T2N0M0	IB	Malignant	103.53	-	-	+，10%	+，90%
L3	179	49	M	Pancreas	Papillary cystadenocarcinoma	*	T2N0M0	IB	Malignant	-	-	-	-	+，90%
L4	180	34	M	Pancreas	Undifferentiated carcinoma	*	T2N1M0	IIB	Malignant	-	-	-	-	+，70%
L5	181	54	M	Pancreas	Adenosquamous carcinoma	*	T2N0M0	IB	Malignant	332	-	-	+，5%	++，90%
L6	182	51	F	Pancreas	Adenosquamous carcinoma with necrosis	*	T2N0M0	IB	Malignant	764	-	-	-	+，80%
L7	183	59	M	Pancreas	Adenosquamous carcinoma	*	T3N1M0	IIB	Malignant	-	-	-	+，10%	+，80%
L8	184	62	F	Pancreas	Squamous cell carcinoma	3	T2N0M0	IB	Malignant	432.5	-	-	-	++，90%
L9	185	62	M	Pancreas	Squamous cell carcinoma	3	T3N0M0	IIA	Malignant	6*5	-	-	+，40%	++，90%
L10	186	67	M	Pancreas	Neuroendocrine carcinoma (sparse)	*	T2N0M0	IB	Malignant	-	-	-	掉片	掉片
L11	187	56	M	Pancreas	Neuroendocrine carcinoma	*	T2N0M0	IB	Malignant	-	-	-	-	+，30%
L12	188	28	M	Pancreas	Neuroendocrine carcinoma	*	T2N1M0	IIIA	Malignant	-	-	-	+，10%	+，40%
L13	189	47	F	Pancreas	Neuroendocrine carcinoma	*	T3N0M0	IIA	Malignant	5	-	-	+，15%	+，20%
L14	190	56	F	Pancreas	Sarcomatoid carcinoma	*	T3N0M0	IIA	Malignant	533	-	-	+，40%	-

Find overlapping cases with this tissue array:

MBC1901

File Format: .xls

Release Date: 2025-01-17 16:02:42
Download

	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16
A	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre
B	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre
C	Bre	Bre	Bre	Bre	Bre	Bre	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun
D	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun
E	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Col	Col	Col	Col
F	Col	Col	Col	Col	Col	Col	Col	Col	Col	Col	Col	Col	Col	Col	Col	Col
G	Col	Col	Col	Col	Col	Col	Col	Col	Col	Col	Col	Col	Col	Col	Col	Col
H	Col	Col	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Pro
I	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Pro
J	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Pan	Pan	Pan	Pan	Pan	Pan	Pan	Pan
K	Pan	Pan	Pan	Pan	Pan	Pan	Pan	Pan	Pan	Pan	Pan	Pan	Pan	Pan	Pan	Pan
L	Pan	Pan	Pan	Pan	Pan	Pan	Pan	Pan	Pan	Pan	Pan	Pan	Pan	Pan

	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16
A	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre
B	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre
C	Bre	Bre	Bre	Bre	Bre	Bre	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun
D	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun
E	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Col	Col	Col	Col
F	Col	Col	Col	Col	Col	Col	Col	Col	Col	Col	Col	Col	Col	Col	Col	Col
G	Col	Col	Col	Col	Col	Col	Col	Col	Col	Col	Col	Col	Col	Col	Col	Col
H	Col	Col	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Pro
I	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Pro
J	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Pan	Pan	Pan	Pan	Pan	Pan	Pan	Pan
K	Pan	Pan	Pan	Pan	Pan	Pan	Pan	Pan	Pan	Pan	Pan	Pan	Pan	Pan	Pan	Pan
L	Pan	Pan	Pan	Pan	Pan	Pan	Pan	Pan	Pan	Pan	Pan	Pan	Pan	Pan

	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16
A	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre
B	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre
C	Bre	Bre	Bre	Bre	Bre	Bre	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun
D	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun
E	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Col	Col	Col	Col
F	Col	Col	Col	Col	Col	Col	Col	Col	Col	Col	Col	Col	Col	Col	Col	Col
G	Col	Col	Col	Col	Col	Col	Col	Col	Col	Col	Col	Col	Col	Col	Col	Col
H	Col	Col	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Pro
I	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Pro
J	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Pan	Pan	Pan	Pan	Pan	Pan	Pan	Pan
K	Pan	Pan	Pan	Pan	Pan	Pan	Pan	Pan	Pan	Pan	Pan	Pan	Pan	Pan	Pan	Pan
L	Pan	Pan	Pan	Pan	Pan	Pan	Pan	Pan	Pan	Pan	Pan	Pan	Pan	Pan